Validation of a self-reported work disability questionnaire for ulcerative colitis by Ramos, A. et al.
Quality Improvement Study Medicine®
OPENValidation of a self-reported work disability
questionnaire for ulcerative colitis
Alexis Ramos, MDa, Mercedes Vergara, MD, PhDb,c,d,
∗
, Luigi Melcarne, MDb, Beatriz Sicilia, MD, PhDa,
Fernando Gomollón, MDb,c,d,e, Xavier Calvet, MDd,
∗
Abstract
Ulcerative colitis (UC) may severely limit patients’ capacity to work. Recently, we validated a work disability questionnaire (WDQ) for
Crohn disease. As UC shares clinical characteristics with Crohn disease, we hypothesized that the questionnaire might also be useful
for UC. The study was aimed to validate the WDQ for use in UC.
Consecutive patients with UC (n=142, 67 women; age 48±1) completed the UC-WDQ and the inflammatory bowel disease
questionnaire-9 (IBDQ-9), and EuroQoL-5D quality-of-life questionnaires. Validation of the UC-WDQ included an assessment of its
construct validity, including: discriminant validity, convergent validity, and reproducibility (test–retest). We also calculated the
intraclass correlation and the Cronbach alpha.
1. Discriminant validity: Mean UC-WDQ scores were 12.8±4.4 (remission phase) and 17.2±6.1 (with clinical activity) (P< .05).
2. Convergent validity: The correlations of UC-WDQ were r=0.74 (P< .001) with IBDQ, r=0.44 (P< .01) with disease activity,
r=0.56 (P< .01) with EuroQoL-5D, and r=0.60 (P< .01) with the EuroQoL-5D visual scale.
3. Reproducibility:
 Test–retest reproducibility: UC-WDQ scores obtained after a 2-week interval were similar (15.8 vs 15.1), (r=0.91, P< .01).
 Intraclass correlation was 0.93 (95% confidence interval 0.92–0.95).
 Cronbach alpha was 0.94.
































































/dAbbreviations: IBD = inflammatory bowel disease, IBDQ = inflammatory bowel disease questionnaire, QoL = quality of life, UC =
ulcerative colitis, UC-WDQ = ulcerative colitis work disability questionnaire, WDQ = work disability questionnaire.
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Characteristics of patients with ulcerative colitis included in the
study.
Patient’s variables Patients characteristics (n=142)
Age (mean±SD), y 48.01±10.28
Sex (male/female) 75/67
Age at diagnosis, n (%)
<16 y 1 (0.7)
Between 16 and 40 y 87 (61.3)
More than 40 y 54 (38.0)
Mayo score, n (%)
<2 inactive disease 33 (23.2)
2–9 mild to moderate activity 104 (73.2)
>9 severe activity 4 (2.8)
Localization, n (%)
Proctocolitis 40 (28.2)
Left colitis 52 (36.6)
Extensive colitis 10 (7.0)
Pancolitis 40 (28.2)
Treatment, n (%)
5-ASA topic 42 (29.6)
5-ASA oral 99 (69.7)
Oral corticosteroid 11 (7.7)
Topical corticosteroid 3 (2.1)
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Ulcerative colitis (UC) is a chronic disease characterized by
remissions and relapses of varying intensity. Incidence of the
disease peaks in early adulthood, a time when a worker’s
productivity tends to be at its highest.[1] Usually, the symptoms
are controlled by medical treatment; however, a small percentage
of patients present refractory evolution[2] with important physical,
emotional, and social effects, reducing health-related quality of life
(QoL) and leading to different degrees of disability.[2]
Disability is defined as a partial or total inability to perform
social roles such as work activity, and is a potential consequence
of disease.[3] Sick leave rates are higher in patients with UC than
in the general population and are associated with lower quality of
life (QoL).[4] Disability can be measured by specific instruments
that may be of use both in clinical practice and in research.
Recently, our group developed and validated a 9-item question-
naire that measured self-reported work disability in patients with
Crohn disease (CD-WDQ)[5] (Annex 1).
As UC and CD share clinical characteristics, we thought that
this instrument might also be useful in patients with UC, although
it has not been validated in this setting. The aim of our study was




Time since diagnosis, y (mean±SD) 9.6±7.9
Surgery, n (%) 8 patients (n=8)
Psychological treatment, n (%) 13 (9.2)
Laboral status, n (%)
Actively working 98 (69)





Educational level, n (%)2. Materials and methods
2.1. Subjects
All patients with UC registered in the inflammatory bowel disease
(IBD) community-based database at theHospital Universitario de
Burgos were evaluated.
Inclusion criteria were: age between 18 and 65 years (working
age); UC diagnosed at least 6 months before the interview;
capacity (judged by the interviewer) to understand and answer
the questionnaires used in the evaluation.
Patients completed the following set of questionnaires
recording clinical data and assessing QoL:Primary 38 (26.8)
Secondary 55 (38.7)1.
2.A self-reported demographic data form.
The Montreal IBD classification,[6] which uses predominantUniversity 49 (34.5)ASA= aminosalicylic acid, SD= standard deviation.phenotypic elements classifying patients according to age at
diagnosis and predominant location of the lesions.
The Mayo score[7] to evaluate disease activity; this score3.
assesses symptoms, their severity and complications, and
classifies activity as remission, mild, moderate, or severe.
The inflammatory bowel disease questionnaire-9 (IBDQ-9),[8]4.
a QoL questionnaire specifically for patients with IBD. It is an
abbreviated, self-administered version of the IBDQ.[9,10]
The EuroQoL-5D,[11] a short self-administered generic5.
questionnaire for QoL. It includes 5 items representing 5
dimensions of health and a visual analog scale that ranges
from 0 (worst imaginable health state) to 100 (best imaginable
health state).
The UC-WDQ,[5] including 9 items (Table 1).6.Additionally, patients were given another UC-WDQ question-
naire to be completed 14 days later, along with an envelope to
return the test to the research team for evaluation of the test–retest
reproducibility. Patients were contacted by telephone to confirm
that their clinical situationhadnot changed in theprevious14days.2.2. Ethical considerations
All eligible patients who agreed to participate provided written
informed consent prior to enrolment. The study was approved by2
the ethical review board of the Hospital de Burgos. The study
conforms to the ethical guidelines of the 1975 Declaration of
Helsinki.
To maintain subject confidentiality and to comply with
applicable data protection and privacy laws and regulations
only the investigator that recruited the questionnaires and
transcribed to database knew the identity of patients2.3. Analysis of psychometric properties
All data obtained from the patients were included in a database.
The psychometric properties of the UC-WDQwere evaluated.[12]
The UC-WDQ’s convergent validity was established by correlat-
ing its scores with disease activity (measured by the Mayo index
and days of hospitalization) and QoL (measured by the IBDQ-9
and the EuroQol-5D). Discriminant validity was measured by
comparing the UC-WDQ scores in patients with active vs inactive
UC, hospitalized vs not hospitalized in the previous year, and
patients who had needed sick leave vs those who had not, also in
the previous year.
Ramos et al. Medicine (2018) 97:39 www.md-journal.comCronbach coefficient was calculated as an indicator of the
internal consistency of the questionnaire.[13] The UC-WDQ was
administered twice (with an interval of at least 2 weeks) to
measure test–retest reproducibility. Test–retest reliability was
also measured using the intraclass correlation coefficient.2.4. Statistical analysis
When the distribution of variables was non-normal, variables
were described using the median and 25th and 75th percentiles.
Differences between medians were established using the Mann–
Whitney or the Kruskal–Wallis test when appropriate. Corre-
lations were calculated with Spearman rank correlation test.
Statistical analysis was performed with the SPSS statistical
package v21.0 (SPSS Inc, Chicago, IL).3. Results
3.1. Patient characteristics
One hundred forty-two consecutive patients with UC were
included. Seventy-five were men and 67 women; mean age was
48.01±10.28 and mean time since disease diagnosis was 9.2±
7.2 years. Characteristics of the patients are displayed in Table 1.3.2. Psychometric properties
3.2.1. Discriminant validity. The UC was considered inactive
when theMayo score was below 2, mild to moderate when it was
between 2 and 9, and severe above 9.
Thirty-three patients were inactive and their mean UC-WDQ
was 12.6±4.5. The 104 patients with mild to moderate disease
had a UC-WDQ of 15.6±5.4 and the 4 patients with severe
active disease had a UC-WDQ of 26.3±8.6 (P< .005).
Mean UC-WDQ was 14.7±5.4 in 124 patients who had not
been hospitalized in the last year vs 18.5±7.1 (P< .05) in the 17
patients who had been hospitalized. Finally, mean UC-WDQ
scoreswere 19.9±6.5 in the 30patientswhohadbeenon sick leave
and 13.9±4.9 (P< .05) in the 111 who had not needed sick leave.
3.2.2. Convergent validity. Spearman correlations were r=0.74
(P< .001) between UC-WDQ and IBDQ, r=0.56 (P< .01)
between UC-WDQ and EuroQoL-5D, and r=0.60 (P< .01)
between UC-WDQ and the EuroQol-5D visual scale. Finally,
there was an inverse correlation between the UC-WDQ and the
Mayo score with a r=0.33 (P< .01).
3.2.3. Reproducibility. No patients presented changes in their
clinical status 14 days after the first interview. Mean disability
scores were similar (15.8 vs 15.1), with a correlation of r=0.91
(P< .01).
Intraclass correlation was 0.93 (95% confidence interval 0.92–
0.95) and Cronbach alpha was 0.94.4. Discussion
Our results show that the UC-WDQ is a valid and reproducible
tool for measuring disability in patients with UC. Evaluating and
preventing disability is important in these patients because most
of them are in working age. In fact, productivity loss is an
important contributor to the notably high costs associated with
UC.[14] Recent studies suggest that between 9% and 19% of
patients with IBD suffer from short-term absences fromwork and
that 19% to 22% have long-term disability,[15] although
disability seems less prevalent in UC than in CD patients.[16]3
Determining the prevalence and the degree of disability in the UC
population would help to evaluate the economic burden of the
sequelae of the disease and to assess the potential usefulness of
early aggressive therapy to prevent disability and reduce long-
term costs.
An interesting finding in our study was the higher correlation
between QoL and disability than between clinical activity and
disability. This may be because the concept of QoL covers many
other aspects, not just the patient’s symptoms; it suggests that
extradigestive findings such as anemia or fatigue may make a
major contribution to work disability in UC.
The medical criteria applied by the authorities for assessing
disability have not been systematized in UC, and access to a
reliable measure of work disability may be an important step
forward. Probably as a consequence, previous studies have
shown that the criteria applied for awarding disability benefits
vary very widely.[17] Having tools to measure disability might
help to reduce this heterogeneity.
For all these reasons, measuring disability has become a hot
spot in IBD. Feagan et al[18] recommended disability as an
endpoint in therapeutic trials and in fact a general disability index
has been recently published.[19–21] The IBD disability index (IBD-
DI) and disability score (IBD-DS) have also been developed using
the WHO’s International Classification of Functioning, Disabili-
ty and Health (ICF).[22] The IBD-DI attempts to measure general
disability in patients with IBD, and has been partially validated in
patients with UC with restorative proctocolectomy.[23] This
validation suggests that IBD-DI may be useful in this subgroup of
patients with UC, although measures of divergent validation or
reliability were not determined.
A limitation of our study is that the questionnaire was produced
in Spanish. Although the validation of translations of the QoL or
work impairment questionnaires has always shown identical
performance when English questionnaires were translated into
Spanish, validation of the English version of the questionnaire is
mandatory.[11,24,25] Another limitation is that we did not use the
work productivity and impairment questionnaire (WPAI) to test
convergent validity.[3] Although itwould be interesting to correlate
acute work impairment with disability, the WPAI has not been
validated for use in patients with UC, even though some studies
have in fact administered it in this setting.[26,27]
In conclusion, our study demonstrates that UC-WDQ is a valid
and reliable self-reported questionnaire for measuring disability
in patients with UC.Acknowledgment
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Ulcerative colitis work disability questionnaire (UC-WDQ)
Instructions for completion:1. Read the questions carefully and circle the answer that best fits
your personal situation.
Answer all the questions, if you leave one out, the2.
questionnaire will not be valid for analysis.
Your answers are totally confidential and will on no account3.
be disclosed.
Answer as sincerely as possible.4.
5. Your answers will contribute to advances in ongoing research
on IBD.
All the questions refer to the past year.6.Thank you very much.1. In the past year, has weight loss related to ulcerative colitis
affected your working capacity?
1. I never lose weight or it does not affect myworking capacity
2. On few occasions
3. Quite often
4. All of the time
In the past year, has ulcerative colitis affected your working
capacity in any way?2.1. Never
2. On few occasions
3. Quite often
4. All of the time
In the past year, has your working capacity been affected by
not having toilet facilities at hand?3.1. I have never been in this situation or it does not affect my
working capacity
2. On few occasions
3. Quite often
4. All of the time
In the past year, has the medication you take for ulcerative
colitis or its secondary effects affected your working capacity4.in any way?4
1. I do not take medication or it does not affect my work
capacity
2. On few occasions
3. Quite often
4. All of the time
In the past year, have you had personal or work-related
problems at your work place due to ulcerative colitis?5.1. I have never had any problems or only minor ones that do
not affect my working capacity
2. On few occasions
3. Quite often
4. All of the time
In the past year, has your working capacity been affected by
you feeling more depressed, anxious, or irritable due to6.ulcerative colitis?
1. I have never felt this way or it does not affect my working
capacity
2. On few occasions
3. Quite often
4. All of the time
In the past year, has tiredness caused by ulcerative colitis
affected your working capacity?7.1. I’ve never felt tired or it doesn’t affect my work capacity
2. On few occasions
3. Quite often
4. All of the time
In the past year, has diarrhea caused by ulcerative colitis
affected your working capacity?8.1. I have never had diarrhea or it does not affect my working
capacity
2. On few occasions
3. Quite often
4. All of the time
In the past year, has your working capacity been affected by
anal incontinence caused by ulcerative colitis?9.1. I’ve never had anal incontinence or it does not affect my
working capacity
2. On few occasions
3. Quite often
4. All of the timeMercedes Vergara orcid: 0000-0002-6971-8657References
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